Showing results (11-20 of 47) with videos related to
Sort By:
Pageof 5
Cancer Research Communications|December 5, 2024
Potential Synergistic Effect between Niraparib and Statins in Ovarian Cancer Clinical TrialsHailei Zhang, Anna Rutkowska, Antonio González-Martín, et al.Gynecologic Oncology|July 20, 2024
Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease after first-line chemotherapy: An ad hoc subgroup analysis of PRIMA/ENGOT-OV26/GOG-3012Mitchell R Kamrava, Antonio Gonzalez-Martin, Bhavana Pothuri, et al.International Journal of Radiation Oncology, Biology, Physics|March 6, 2007
Practice patterns of radiotherapy in cervical cancer among member groups of the Gynecologic Cancer Intergroup (GCIG)David K Gaffney, Andreas Du Bois, Kailash Narayan, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 5, 2009
Patterns of care for radiotherapy in vulvar cancer: a Gynecologic Cancer Intergroup studyDavid K Gaffney, Andreas Du Bois, Kailash Narayan, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 6, 2023
Optimizing disease progression assessment using blinded central independent review and comparing it with investigator assessment in the PRIMA/ENGOT-ov26/GOG-3012 trial: challenges and solutionsThomas J Herzog, Shaun A Wahab, Mansoor R Mirza, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2024
Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase InhibitorAngelina Tjokrowidjaja, M L Friedlander, Jonathan A Ledermann, et al.Cancer|March 19, 2021
Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysisChee Khoon Lee, Michael L Friedlander, Angelina Tjokrowidjaja, et al.European Journal of Cancer (Oxford, England : 1990)|June 1, 2023
Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancerAntonio González-Martín, Bhavana Pothuri, Ignace Vergote, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 9, 2026
Differences in first-line chemosensitivity assessed by ELIMination rate constant K in advanced serous ovarian cancer: evidence from Western and Japanese Trials in a Gynecologic Cancer InterGroup meta-analysisPauline Corbaux, Benoit You, Iain McNeish, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 19, 2025
Identifying high-risk relapse in early-stage I to II ovarian cancer using the CA125 ELIMination rate constant K (KELIM) score: a Gynecologic Cancer InterGroup individual patient-data meta-analysisPauline Corbaux, Benoit You, Tatsuo Kagimura, et al.Pageof 5